Immunis Chief Business Officer Mark Cabato to Deliver Keynote at the Drug Discovery Strategic Summit

IRVINE, Calif.--()--Immunis, Inc., a leading biotechnology company forging innovative cellular secretome therapies for age and disease-related immune decline, is delighted to announce that its Chief Business Officer, Mark Cabato, will be a keynote speaker at this year's Drug Discovery Strategic Summit.

Mark is set to delve deeper into Immunis' cutting-edge cellular secretome technology, which has shown pre-clinical efficacy in improving muscle regeneration and function as well as benefiting metabolism. The investigational secretome product, IMMUNA, is currently being tested in a Phase 1/2a clinical trial in elderly adults with muscle atrophy. Conference attendees will learn more about Immunis’ mission to advance a pioneering secretome therapy to rejuvenate the quality of life for older adults. "Age-related and disuse-induced muscle atrophy is an underappreciated disease afflicting millions at a societal cost in the tens of billions," says Mr. Cabato. "This summit provides an ideal platform to discuss how our novel, multi-bioactive secretome shows promise in this area of high unmet need and economic burden."

The Drug Discovery Strategic Summit has historically been a melting pot for revolutionary ideas in the medical world. This year, it continues to cement its reputation as a hub for innovation and thought leadership. Stakeholders, industry enthusiasts, and scientists are eagerly awaiting to hear more about Immunis' forward-looking approach on secretome therapeutics and the exciting future that lies ahead to address age-related illnesses.

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit:

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.